| Recruiting | A Study of the TheraBionic P1 Device in Breast Cancer NCT07218432 | Barbara Ann Karmanos Cancer Institute | N/A |
| Recruiting | Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer NCT07379918 | Assistance Publique - Hôpitaux de Paris | — |
| Not Yet Recruiting | Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors NCT07524322 | Regor Pharmaceuticals Inc. | Phase 1 |
| Not Yet Recruiting | Study of Multi-mode Thermal Therapy Combined With Immunotherapy In Patients With HER2-negative Breast Cancer W NCT07466927 | Fudan University | Phase 2 |
| Recruiting | A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer NCT07483307 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Recruiting | Study on the Treatment of HER2-negative Breast Cancer Brain Metastases With Radiotherapy Combined With Anlotin NCT07396454 | The First Affiliated Hospital with Nanjing Medical University | Phase 2 |
| Not Yet Recruiting | A Ph II Study of the TheraBionic P1 Device in Subjects With Hormone Positive Breast Cancer NCT07227831 | Barbara Ann Karmanos Cancer Institute | N/A |
| Not Yet Recruiting | CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment NCT07366112 | Peking University People's Hospital | Phase 2 |
| Recruiting | Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Stan NCT07281833 | West German Study Group | Phase 3 |
| Recruiting | ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor an NCT07198724 | Sarah Sammons, MD | Phase 1 / Phase 2 |
| Recruiting | Breast Re-irradiation After Second Ipsilateral Lumpectomy NCT06867484 | Youssef Zeidan | N/A |
| Recruiting | Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer NCT06774027 | University of California, San Francisco | — |
| Recruiting | Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Met NCT06982521 | Relay Therapeutics, Inc. | Phase 3 |
| Recruiting | ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cance NCT06970912 | Peking University People's Hospital | Phase 2 |
| Not Yet Recruiting | Real-world Study of SKB264 Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast NCT06993506 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | — |
| Recruiting | Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Riboci NCT06953882 | Yale University | Phase 2 |
| Recruiting | A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas NCT06999187 | Dren Bio | Phase 1 |
| Recruiting | NearWave Optical Molecular Monitoring NCT06744465 | Indiana University | N/A |
| Recruiting | Reverse HER2-negative Immune Resistant Breast Cancer NCT06731140 | Fudan University | Phase 2 |
| Recruiting | BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growt NCT06756932 | BeOne Medicines | Phase 1 |
| Recruiting | Adherence to Aromatase Inhibitors ± Abemaciclib Treatment in Patients With Early-stage HER2-negative Breast Ca NCT06650423 | Institute of Oncology Ljubljana | — |
| Recruiting | Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i. NCT06382948 | MedSIR | Phase 3 |
| Not Yet Recruiting | Improvement of Quality of Life Through Supportive Treatments for Hormone Therapy - Related Symptoms in Patient NCT06407401 | European Organisation for Research and Treatment of Cancer - EORTC | Phase 3 |
| Recruiting | Pilot Study of Neoadjuvant Chemotherapy Combined With Immunotherapy and Multimodal Thermal Therapy for HER2-ne NCT06636591 | Fudan University | N/A |
| Recruiting | A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer NCT06678269 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Recruiting | Immunologic Targeting of ESR1 Receptor for Hormone Receptor Expressing Metastatic Breast Cancer NCT06691035 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Recruiting | Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer NCT06518837 | Rutgers, The State University of New Jersey | Phase 2 |
| Recruiting | TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd NCT06533826 | Ana C Garrido-Castro, MD | Phase 2 |
| Recruiting | Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer NCT06649331 | Fudan University | Phase 2 |
| Recruiting | Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant with Neoadjuvant Therapy NCT05989347 | Yale University | Phase 1 |
| Recruiting | A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer NCT06568692 | Processa Pharmaceuticals | Phase 2 |
| Recruiting | Organoid-based Functional Precision Therapy for Advanced Breast Cancer NCT06102824 | Guangdong Provincial People's Hospital | Phase 2 |
| Recruiting | Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab NCT06516289 | Fudan University | Phase 2 |
| Recruiting | Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-neg NCT06488378 | Dana-Farber Cancer Institute | Phase 1 |
| Active Not Recruiting | Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer NCT06590857 | RayzeBio, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC NCT06351332 | Filipa Lynce, MD | Phase 1 / Phase 2 |
| Recruiting | DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Metastatic Breast Cancer Patients NCT06388122 | Mayo Clinic | — |
| Active Not Recruiting | BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and O NCT06253195 | BeiGene | Phase 1 |
| Unknown | New Digital Person-based Care Model in Patients With HER2-negative Advanced Breast Cancer NCT06348654 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Active Not Recruiting | Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors NCT06334432 | Nuvation Bio Inc. | Phase 1 / Phase 2 |
| Recruiting | DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs NCT06176261 | Sarah Sammons, MD | Phase 2 |
| Recruiting | Intrathecal Chemotherapy Through Ommaya Reservoir Upon Her-2 Negative Breast Cancer With Leptomeningeal Metast NCT06230055 | Fudan University | Phase 4 |
| Recruiting | Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) NCT05512364 | European Organisation for Research and Treatment of Cancer - EORTC | Phase 3 |
| Recruiting | BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Soli NCT06120283 | BeOne Medicines | Phase 1 |
| Unknown | ANG1005 in Leptomeningeal Disease From Breast Cancer NCT03613181 | Angiochem Inc | Phase 3 |
| Completed | Study of Predictors of Clinical Outcomes in Patients With HR+ and HER2-low/Negative Breast Cancer NCT06040593 | Daiichi Sankyo | — |
| Completed | Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations NCT05904730 | Lynkcell Europe | Phase 1 |
| Withdrawn | Fulvestrant + Neratinib In Breast Cancer NCT04901299 | Massachusetts General Hospital | Phase 2 |
| Active Not Recruiting | Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metasta NCT05826964 | University of Miami | Phase 2 |
| Recruiting | A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Co NCT05824975 | GI Innovation, Inc. | Phase 1 / Phase 2 |
| Completed | First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors NCT05759949 | Relay Therapeutics, Inc. | Phase 1 |
| Completed | Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer NCT05101564 | Jennifer Lee Caswell-Jin | Phase 2 |
| Suspended | Fasting Mimicking Diet Program to ImpRovE ChemoTherapy in Hormone Receptor Postive (HR+), HER2- Breast Cancer NCT05503108 | Leiden University Medical Center | Phase 3 |
| Unknown | CLEAR-B: Cancer Landscape - Early Adjuvant Retrospective Registry - Breast Cancer NCT05870813 | Institut fuer Frauengesundheit | — |
| Active Not Recruiting | Neoadjuvant Concomitant Modulated Electro-hyperthermia in HER2-negative Breast Cancer NCT05889390 | Semmelweis University | Phase 2 / Phase 3 |
| Recruiting | PRE-I-SPY Phase I/Ib Oncology Platform Program NCT05868226 | QuantumLeap Healthcare Collaborative | Phase 1 |
| Recruiting | (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer NCT05607004 | Atossa Therapeutics, Inc. | Phase 2 |
| Recruiting | OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk NCT05333328 | Gangnam Severance Hospital | Phase 4 |
| Active Not Recruiting | Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer NCT05982093 | SOLTI Breast Cancer Research Group | Phase 2 |
| Recruiting | Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC) NCT05660083 | The Methodist Hospital Research Institute | Phase 2 |
| Recruiting | SNF Platform Study of HR+/ HER2-advanced Breast Cancer NCT05594095 | Fudan University | Phase 2 |
| Completed | Neoadjuvant Treatment of Locally-advanced Breast Cancer Patients With Ribociclib and Letrozole NCT05163106 | University Hospital, Akershus | Phase 2 |
| Recruiting | Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy NCT05582499 | Fudan University | Phase 2 |
| Recruiting | Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Ad NCT05452213 | Institut fuer Frauengesundheit | Phase 4 |
| Recruiting | Role of the Immune Environment in Response to Therapy in Breast Cancer NCT05396612 | Abramson Cancer Center at Penn Medicine | — |
| Active Not Recruiting | Onvansertib + Paclitaxel In TNBC NCT05383196 | Antonio Giordano, MD | Phase 1 / Phase 2 |
| Recruiting | Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor NCT05467891 | Oana Danciu | Phase 2 |
| Recruiting | Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer NCT05524584 | University of California, Irvine | Phase 2 |
| Recruiting | Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmocicli NCT05508906 | Olema Pharmaceuticals, Inc. | Phase 1 |
| Recruiting | DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer NCT05504707 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Completed | Study to Evaluate the Extended Overall Survival (OS) Data From PARSIFAL Study (The PARSIFAL-LONG Study) NCT06525675 | MedSIR | — |
| Terminated | A Study in Patients With Advanced Breast Cancer NCT04942054 | Sun Pharma Advanced Research Company Limited | Phase 1 |
| Active Not Recruiting | A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy i NCT05275777 | National University Hospital, Singapore | Phase 1 / Phase 2 |
| Recruiting | CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer NCT05029999 | University of Texas Southwestern Medical Center | Phase 1 |
| Unknown | Anlotinib Combined With Chemotherapy for the Treatment of HER2 Negative Advanced Breast Cancer NCT05334147 | The First Affiliated Hospital with Nanjing Medical University | — |
| Completed | To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients NCT05253053 | TransThera Sciences (Nanjing), Inc. | Phase 1 / Phase 2 |
| Terminated | (VELA) Study of BLU-222 in Advanced Solid Tumors NCT05252416 | Blueprint Medicines Corporation | Phase 1 |
| Recruiting | A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palboc NCT04985266 | Royal Marsden NHS Foundation Trust | Phase 2 |
| Completed | Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast NCT05340413 | SOLTI Breast Cancer Research Group | Phase 2 |
| Unknown | Gemcitabine Combined With Eribulin Regimen in the Treatment of Second-line Above Recurrent HER2-negative Breas NCT05263882 | Fifth Affiliated Hospital, Sun Yat-Sen University | Phase 2 |
| Completed | D4 Choline Breast PET/CT NCT04276272 | Imperial College London | — |
| Active Not Recruiting | Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer NCT05150652 | Irada Ibrahim-zada | Phase 2 |
| Recruiting | First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advance NCT05216432 | Relay Therapeutics, Inc. | Phase 1 |
| Unknown | Efficacy and Safety of Combinition of Camrelizumab in Second-line Neoadjuvant Chemotherapy and Adjuvant Therap NCT04848454 | Peking University First Hospital | Phase 2 |
| Active Not Recruiting | ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer NCT06570031 | Ono Pharmaceutical Co., Ltd. | Phase 1 |
| Terminated | Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibito NCT04738292 | University of Wisconsin, Madison | Phase 2 |
| Completed | Retrospective Study of 2nd-line Therapies After CDK4/6i + Hormonal Therapy in HR+/HER2- Advanced Breast Cancer NCT05173103 | University of Milano Bicocca | — |
| Completed | A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer NCT05054374 | Memorial Sloan Kettering Cancer Center | Phase 1 / Phase 2 |
| Unknown | Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Can NCT05025735 | Saint Luke's Health System | Phase 2 |
| Terminated | Biology Guided Therapy for Breast Cancer for ER Positive NCT04965688 | Inova Health Care Services | Phase 2 |
| Recruiting | Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer NCT04573231 | University of Wisconsin, Madison | Phase 2 |
| Unknown | Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors NCT04764084 | Peking University Cancer Hospital & Institute | Phase 1 |
| Completed | Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid NCT04742959 | TransThera Sciences (Nanjing), Inc. | Phase 1 / Phase 2 |
| Unknown | Eribulin Combined With Anlotinib in Metastatic HER2 Negative Breast Cancer NCT04624711 | The First Affiliated Hospital with Nanjing Medical University | Phase 2 |
| Recruiting | Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer NCT05305924 | The Methodist Hospital Research Institute | Phase 2 |
| Completed | Functional Precision Oncology for Metastatic Breast Cancer NCT04450706 | University of Utah | N/A |
| Active Not Recruiting | Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy NCT04762979 | Marina N Sharifi | Phase 2 |
| Active Not Recruiting | Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the NCT04551495 | Jules Bordet Institute | Phase 2 |
| Recruiting | SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells NCT04150042 | General Oncology, Inc. | Phase 1 |
| Active Not Recruiting | Niraparib + Dostarlimab In BRCA Mutated Breast Cancer NCT04584255 | Dana-Farber Cancer Institute | Phase 2 |
| Recruiting | Clinical Study of Breast Conserving Surgery Combined With Intraoperative Radiotherapy for Early Breast Cancer NCT06375798 | Hebei Medical University Fourth Hospital | — |
| Completed | A Study to Investigate the Biological Effects of AZD9833 in Women With ER-positive, HER2 Negative Primary Brea NCT04588298 | AstraZeneca | Phase 2 |
| Recruiting | The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) NCT04585750 | PMV Pharmaceuticals, Inc | Phase 1 / Phase 2 |
| Active Not Recruiting | Sacituzumab Govitecan in Primary HER2-negative Breast Cancer NCT04595565 | GBG Forschungs GmbH | Phase 3 |
| Terminated | Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered NCT04504331 | Jennifer Lee Caswell-Jin | Phase 1 |
| Terminated | A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002) NCT04504916 | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 2 |
| Active Not Recruiting | Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC NCT04448886 | Ana C Garrido-Castro, MD | Phase 2 |
| Recruiting | Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast NCT04576143 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 2 / Phase 3 |
| Unknown | Study of Tislelizumab Plus Chemotherapy vs Chemotherapy as Perioperative Treatment in Participants With HER2 N NCT04498793 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 |
| Recruiting | To Identify Primary Resistance to CDK4/6 Inhibitors in Breast Cancer NCT04660435 | Fondazione Sandro Pitigliani | — |
| Completed | A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breas NCT04505826 | Olema Pharmaceuticals, Inc. | Phase 1 / Phase 2 |
| Unknown | AT Versus TP as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer NCT04499118 | Sichuan Provincial People's Hospital | Phase 2 |
| Recruiting | Sacituzumab Govitecan In TNBC NCT04230109 | Massachusetts General Hospital | Phase 2 |
| Active Not Recruiting | Study of Pembrolizumab in Metastatic HER2-negative Breast Cancer Patients With APOBEC3B Mutation NCT03989089 | University of Malaya | Phase 2 |
| Active Not Recruiting | Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid T NCT03983954 | NeoTX Therapeutics Ltd. | Phase 1 |
| Terminated | A Phase 1 Study of [225Ac]-FPI-1434 Injection NCT03746431 | Fusion Pharmaceuticals Inc. | Phase 1 |
| Completed | Efficacy and Safety of BGB-290 in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA M NCT03575065 | BeiGene | Phase 2 |
| Unknown | Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With NCT03412643 | NSABP Foundation Inc | Phase 2 |
| Active Not Recruiting | Monitoring Response to Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Using High-speed MR Spectroscop NCT03568448 | New Mexico Cancer Research Alliance | — |
| Completed | A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers NCT03251378 | Hutchison Medipharma Limited | Phase 1 |
| Terminated | Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer NCT03294694 | Dana-Farber Cancer Institute | Phase 1 |
| Active Not Recruiting | Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating P NCT02315196 | Rutgers, The State University of New Jersey | Phase 2 |
| Terminated | Phase II Study of Everolimus Beyond Progression NCT02269670 | Emory University | Phase 2 |
| Terminated | Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kid NCT02273752 | Emory University | Phase 2 |
| Completed | Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metast NCT02015559 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Completed | Post-Marketing Surveillance Study of Eribulin on the Status and Factors for the Development of Peripheral Neur NCT02371174 | Eisai Co., Ltd. | — |
| Terminated | Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer NCT01938833 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 1 / Phase 2 |
| Active Not Recruiting | Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing NCT01953588 | Alliance for Clinical Trials in Oncology | Phase 3 |
| Completed | Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated NCT02225470 | Eisai Co., Ltd. | Phase 3 |
| Completed | Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabin NCT01881230 | Celgene | Phase 2 / Phase 3 |
| Completed | Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Br NCT01818063 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 |
| Active Not Recruiting | BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer NCT01791478 | Vanderbilt-Ingram Cancer Center | Phase 1 |
| Completed | Exosomal and Free Extracellular RNAs and Proteins as Predictive Biomarkers for HER2 Therapies in Breast Cancer NCT01840306 | Cancer Trials Ireland | — |
| Completed | Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locall NCT01705691 | NSABP Foundation Inc | Phase 2 |
| Completed | Trial of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HE NCT01527487 | SCRI Development Innovations, LLC | Phase 2 |
| Terminated | Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive NCT01368263 | Washington University School of Medicine | Phase 2 |
| Unknown | Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients NCT01372579 | Northwestern University | Phase 2 |
| Terminated | RO4929097 and Letrozole in Treating Post-Menopausal Women With Hormone Receptor-Positive Stage II or Stage III NCT01208441 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery NCT01234532 | University of Maryland, Baltimore | Phase 2 |
| Completed | Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast NCT01104259 | University of Washington | Phase 1 |
| Terminated | Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced, Metastatic, o NCT01151449 | National Cancer Institute (NCI) | Phase 2 |
| Completed | RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors NCT01158274 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer NCT01042379 | QuantumLeap Healthcare Collaborative | Phase 2 |
| Withdrawn | Breast-Conserving Surgery Followed by Radiation Therapy With MRI-Detected Stage I or Stage II Breast Cancer NCT01100489 | Case Comprehensive Cancer Center | Phase 2 |
| Completed | Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer NCT01037790 | Abramson Cancer Center at Penn Medicine | Phase 2 |
| Terminated | Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breas NCT00679029 | University of Nebraska | Phase 2 |
| Completed | Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer NCT00733408 | University of Washington | Phase 2 |
| Completed | Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting NCT00618657 | University of California, Irvine | Phase 2 |
| Terminated | Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA B NCT00194792 | University of Washington | Phase 2 |
| Completed | 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid NCT00031681 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Paclitaxel With or Without Trastuzumab in Treating Patients With or Without HER-2/Neu Breast Cancer That is In NCT00003440 | National Cancer Institute (NCI) | Phase 3 |